Reference
Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab Clinical Genitourinary Cancer : 18 Sep 2023. Available from: URL: https://doi.org/10.1016/j.clgc.2023.09.003
Rights and permissions
About this article
Cite this article
Cabozantinib + nivolumab and ipilimumab/nivolumab have differing safety profiles. Reactions Weekly 1979, 6 (2023). https://doi.org/10.1007/s40278-023-47733-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-47733-x